UnknownPhase 4

Memantine Treatment in Alzheimer's Disease Patients

222 participantsStarted 2017-07-15

Plain-language summary

The aim of this study is to investigate whether there will be any efficacy difference of Memantine treatment in different cognitive severity AD patients stratified with BPSD

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Probable AD based on the diagnosis criteria of NIA-AA guideline (the U.S. National Institute on Aging and Alzheimer's Association guideline, McKhann et al, 2011\[8\];
✓. Male or female, 50 years and older ;
✓. All inpatients or outpatients recruited into this study must meet MMSE score ≤24 points, patients with MMSE score as 21-24 points will be enrolled into mild group, patients with MMSE score as 10-20 points will be enrolled into moderate group, patients with MMSE score less than 10 points will be enrolled into severe group.
✓. Have a reliable caregiver who can accompany the patient to the site to complete the required study procedures;
✓. Provide the informed consent.

Exclusion criteria

✕. Patients with disturbance of consciousness of any causes;
✕. Patients with severe aphasia or physical disability who were unable to complete neuropsychological examination;
✕. Patients with mental illness;
✕. Patients with a history of alcoholism and drug addiction, or traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus and other neurological disorders causing cognitive impairment;
✕. Patients with systemic diseases causing dementia (e.g. liver and kidney insufficiency, endocrine disorders, vitamin deficiency);
✕. Patients with a history of ischemic or hemorrhagic cerebrovascular diseases, and vascular diseases (stroke foci) as confirmed by imaging examination;
✕. Subjects who are unwilling or unable to abide by the study requirement.

What they're measuring

ADAS-cog change

Timeframe: ADAD-cog Change from baseline to 24 weeks

Trial details

NCT IDNCT03168997

SponsorWei Cuibai

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09-30

View on ClinicalTrials.gov More Alzheimer Disease trials